menu
    • menu
    [{"orgOrder":0,"company":"Univercells","sponsor":"Exyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Univercells","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Univercells \/ Univercells","highestDevelopmentStatusID":"1","companyTruncated":"Univercells \/ Univercells"},{"orgOrder":0,"company":"Univercells","sponsor":"Altamira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BERMUDA","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"mRNA-Based Vaccine","moa":"SARS-CoV-2 S","graph1":"Oncology","graph2":"Preclinical","graph3":"Univercells","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Univercells \/ Univercells","highestDevelopmentStatusID":"4","companyTruncated":"Univercells \/ Univercells"},{"orgOrder":0,"company":"Univercells","sponsor":"Codagenix","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"SARS-CoV-2 Vaccine, Live Attenuated","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Univercells","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Univercells \/ Univercells","highestDevelopmentStatusID":"10","companyTruncated":"Univercells \/ Univercells"},{"orgOrder":0,"company":"Univercells","sponsor":"ReiThera","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Adenoviral Vector-Based Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Univercells","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Univercells \/ Univercells","highestDevelopmentStatusID":"1","companyTruncated":"Univercells \/ Univercells"}]

    Find Clinical Drug Pipeline Developments & Deals by Univercells

    Menu

    Univercells

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Univercells

                            Belgium arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Univercells

                            Belgium arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : mRNA-Based Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Altamira Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Altamira Collaborates with Univercells On Nanoparticle-Delivered mRNA Vaccines

                            Details : Under the agreement, Univercells will test a proprietary mRNA vaccine with Altamira’s SemaPhore platform to prevent, treat, and cure diseases across oncology to infectious diseases.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 25, 2024

                            Lead Product(s) : mRNA-Based Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Altamira Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Univercells

                            Belgium arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Univercells

                            Belgium arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SARS-CoV-2 Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Recipient : Codagenix

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Codagenix and Univercells Announce Research Collaboration on Undisclosed, High-Priority Human Vaccine

                            Details : Partnership will utilize scale-X™ for Codagenix's pipeline including vaccine candidates for SARS-CoV-2 COVI-VAC™, respiratory syncytial virus (CodaVax™-RSV); influenza (CodaVax™-H1N1); dengue virus; and triple negative breast cancer (using a rati...

                            Product Name : Covi-vac

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 20, 2021

                            Lead Product(s) : SARS-CoV-2 Vaccine, Live Attenuated

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Recipient : Codagenix

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Univercells

                            Belgium arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Univercells

                            Belgium arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Exyte

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Exyte and Univercells Combine Forces for Rapid Deployment of Vaccine

                            Details : Through this partnership, an integrated plant design combines Exyte’s prefabricated modular construction system, ExyCell, with Univercells Technologies’ NevoLine biomanufacturing platform featuring the scale-X fixed-bed bioreactor at its core.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            May 14, 2020

                            Lead Product(s) : COVID-19 Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Exyte

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Univercells

                            Belgium arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Univercells

                            Belgium arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adenoviral Vector-Based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : ReiThera

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ReiThera, LEUKOCARE and Univercells Join Forces to Fast-track Development of a Single-dose Adenovirus-based CO...

                            Details : The pan-European consortium of ReiThera, LEUKOCARE and Univercells brings together an adenoviral vector-based vaccine candidate targeting the spike protein of SARS-CoV-2.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 23, 2020

                            Lead Product(s) : Adenoviral Vector-Based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : ReiThera

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth